Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin for diabetic proteinuria in chronic kidney disease
IRCT20090905002417N23Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Linagliptin with Placebo (2 arms). Primary endpoints: proteinuria, serum creatinine and 3 more. Started Mar 2019; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20090905002417N23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090905002417N23.